Introduction. Antagonism of CC chemokine receptor type 1 (CCR1) may provide a novel treatment approach for women with symptomatic endometriosis. Studies of CCR1 antagonists in these patients have not been reported. Material and methods. Women (n = 110; 18-45 years) with symptomatic endometriosis were randomized to BAY 86-5047 or placebo for 12 weeks. Pelvic pain was assessed using the visual analogue scale (VAS) and women recorded the intake of pain medication in a diary. The primary efficacy outcome was a composite of the absolute change in VAS score and the cumulative change in consumption of analgesics between baseline and the end of treatment. Safety assessments included adverse events, blood and urine evaluation and electrocardiography. Results. Mean VAS scores decreased from 64.8 mm at baseline to 49.2 mm at week 12 in the BAY 86-5047 group and from 67.2 mm to 47.8 mm in the placebo group. The proportion of women using analgesics decreased from 33.9% to 11.5% or from 44.4% to 15.4% for patients who received BAY 86-5047 or placebo, respectively. There was no significant difference between the two treatment groups in terms of change in VAS scores (p = 0.45) or intake of analgesics (p = 0.82). A three-step sensitivity analysis failed to show superiority of BAY 86-5047 over placebo (p = 0.67). BAY 86-5047 was well tolerated and no significant safety concerns arose during the study. Conclusions. Based on these results, BAY 86-5047 is unlikely to be useful in the treatment of women with endometriosis-associated pelvic pain.
Introduction
Endometriosis is a sex hormone-dependent inflammatory disease defined by the presence of endometrium-like tissue (endometriotic lesions) outside the lining of the uterus, predominantly in the pelvic region (1) . The growth of this ectopic tissue induces a chronic inflammatory reaction, and women with endometriosis may experience dysmenorrhea, chronic pelvic pain, dyspareunia, chronic fatigue and sub-fertility (2) . Endometriosis is estimated to affect up to 10% of women during their reproductive years, with disease severity varying between individuals (1).
Endometriotic lesions can be removed by laparoscopic surgery, which may relieve pain and enhance fertility in ª 2017 Nordic Federation of Societies of Obstetrics and Gynecology, Acta Obstetricia et Gynecologica Scandinavica 96 (2017) 694-701 some cases (3) . Current pharmacological therapies for endometriosis treat disease-associated pelvic pain and comprise primarily non-steroidal anti-inflammatory drugs and hormonal treatments that suppress endogenous estradiol levels, including combined oral contraceptives, progestins and gonadotropin-releasing hormone agonists (4) . There is evidence that these therapies can provide some symptomatic relief, but findings from patient surveys suggest that, overall, their efficacy is unsatisfactory in many women (5) . Neither surgical nor medical therapies have confirmed superior efficacy in treating endometriosisassociated pelvic pain (EAPP) and current guidelines do not recommend either treatment modality over the other (2) .
Over the past decade, there has been increased interest in developing non-hormonal therapies that target the pain and inflammatory pathways fundamental to endometriosis (6) . However, regulatory approval has yet to be obtained for any non-hormonal treatment for the disease. Of particular interest are immunomodulatory strategies aimed at reducing disease-associated chronic inflammation (7) . Such therapies are based on observations that the pathogenesis of endometriosis is characterized by excessive leukocyte numbers, principally macrophages and T cells, in both endometriotic implants and within the surrounding peritoneal fluid (8) . The recruitment of leukocytes to inflammatory sites is mediated through the binding of chemokines (low molecular weight cytokines) to their cognate receptors (9), a process that propagates the inflammatory state. One of the principal chemokines present in the peritoneal fluid of women with endometriosis, accounting for 70% of its monocyte chemotactic activity (10) , is RANTES (regulated upon activation, normal T-cell expressed and secreted cytokine; also known as CCL3) (8) . CC chemokine receptor type 1 (CCR1) is a chemokine receptor with high affinity for RANTES (9) , which is present at increased levels on the peritoneal macrophages of women with endometriosis (8) . Binding of chemokines to CCR1 is associated with pro-inflammatory actions, including leukocyte migration and upregulation of integrins, such as CD11b, to promote leukocyte adherence to the endothelium (11) . For this reason, CCR1 has been proposed as a contributory factor to endometriosis-associated inflammation, and may constitute a novel non-hormonal target for the development of new drugs to treat this disease.
Several CCR1 antagonists have already been developed, with the intention of reducing pain symptoms in chronic inflammatory diseases (11) . The small molecule antagonist BAY 86-5047 has been shown to bind selectively to CCR1 with high affinity (12) , which consequently prevents binding of the proinflammatory chemokines CCL3, CCL5 and CCL7 to this receptor (13) . BAY 86-5047 has been studied in several chronic inflammatory conditions, including multiple sclerosis (13) and renal fibrosis (14) . This study aimed to evaluate the efficacy, safety and tolerability of BAY 86-5047 given orally over 12 weeks for the treatment of women with EAPP.
Material and methods
The study was a multicenter, randomized, placebo-controlled, parallel-group, double-blind trial. A total of 28 centers took part, in seven countries. Women of reproductive age (18-45 years) were eligible for inclusion in the study if they met the following criteria:
• endometriosis, as determined by diagnostic laparoscopy or laparotomy between 24 months and six weeks prior to screening (visit 1)
• a minimum pelvic pain score of 40 mm on the visual analogue scale (VAS) at screening and at baseline
• willingness to use a barrier contraceptive method (unless bilateral tubal ligation had been performed previously), but no hormonal contraception
• willingness to use only ibuprofen (up to 3 9 400 mg tablets per day) to treat pain associated with endometriosis.
Participants were assigned to BAY 86-5047 or placebo by means of a blocked randomization list generated by the sponsor's central randomization service. Both participants and investigators were blinded to treatment allocation. Both treatments were administered as two tablets (taken three times daily). The treatment was taken continuously with no medication-free days.
The study period comprised a screening phase of four to eight weeks prior to treatment and a 12-week treatment phase, in which BAY 86-5047 was titrated up to a dose of 1800 mg per day over the first 10 days. Participants visited the study site at screening, start of treatment (baseline) and at weeks 1, 2, 4, 8 and 12 of treatment. A follow-up visit took place at week 16. Participants were given a diary to record their intake of treatment and analgesics (ibuprofen), pain severity using the VAS and the occurrence of adverse events (AEs).
Pelvic pain was assessed using the VAS at baseline (visit 2, the first day of treatment) and at weeks 4, 8, 12 and 
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The potent, selective CC chemokine receptor type 1 (CCR1) antagonist BAY 86-5047 is ineffective for the treatment of women with endometriosis-associated pelvic pain when administered for 12 weeks. 16 . Women were asked to make a single mark on the line indicating their pain associated with endometriosis during the time window of the preceding four weeks. Biberoglu and Behrman (B&B) scores (15) were measured at baseline and at weeks 12 and 16 to assess the severity of symptoms, based on participants' self-assessment of pain and gynecological palpation by the attending clinician. Safety outcomes were monitored throughout the study, including AEs, electrocardiograms, bleeding patterns and laboratory evaluations.
The primary efficacy variable was a composite comprising the individual absolute change in EAPP, measured by VAS score (mm), and the cumulative change in consumption of analgesics between baseline and the end of treatment. The secondary efficacy variables were change in VAS score between baseline and week 12, or premature discontinuation, change in intake of analgesics from baseline to week 12, change in B&B scores from baseline to week 12 and global assessment of efficacy by the patient and investigator at week 12. AEs, including clinically relevant changes in safety parameters (such as standard laboratory parameters or vital signs), were summarized by treatment group according to the Medical Dictionary for Regulatory Activities.
Competent authorities and the responsible ethics committees/institutional review boards of the participating centers approved the study protocol between 23 September 2004 and 9 March 2006 (Supporting Information  Table S1 ) and all participants provided written informed consent. The study (ClinicalTrials.gov identifier: NCT00185341; EudraCT number: 2004-000630-37) was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki and Good Clinical Practice guidelines of the International Conference on Harmonisation.
Statistical analyses
Sample size was determined based on an expected difference in VAS score reduction of 25 mm between the BAY 86-5047 and placebo arms, with a standard deviation of approximately 35 mm for both groups. Using an error margin for a one-sided test (a = 0.025) and a power of 0.9 (b = 0.1), it was calculated that 43 patients would be required in each treatment arm to detect superiority of BAY 86-5047 over placebo. Given an anticipated dropout rate of 25%, at least 58 patients were required in each treatment group.
The primary efficacy variable was tested using Tamhane and Logan's approximate likelihood ratio test (16) and a sensitivity analysis, using a three-step hierarchical testing procedure (designed to demonstrate the superiority of at least one component within the composite primary endpoint while both components are non-inferior) according to R€ ohmel et al. (17) .
Superiority analysis was used to test change in VAS and B&B scores between baseline and week 12. Descriptive statistics were used to analyze VAS scores, intake of analgesic medication at baseline and week 12, and safety parameters. B&B scores were assessed using descriptive statistics and responder analysis at baseline, week 12 and follow up. Global assessment of efficacy was assessed at the end of treatment using the Clinical Global Impression scale (18) .
Results

Participant characteristics
The participant flow diagram is shown in Figure 1 . Following screening, 110 participants were eligible for the study between February 2005 and February 2007. Participants (54 receiving placebo, 56 receiving BAY 86-5047) were randomized and constituted the full analysis set for the study.
Participant demographic and baseline clinical data are displayed in Table 1 . Almost all the women enrolled (98.2%) were Caucasian. Where data were available, the majority of women were categorized as disease stage III or IV [according to the revised American Society for Reproductive Medicine (rASRM) classification]. The two groups were similar in terms of age, ethnicity, body mass index and rASRM stage of endometriosis.
Efficacy variables after 12 weeks of treatment
Primary efficacy variables. Within the full analysis set, there was no significant difference in the primary endpoint between the placebo and BAY 86-5047 groups (p = 0.75) after 12 weeks of treatment using the approximate likelihood ratio test. Similarly, the three-step sensitivity analysis failed to demonstrate superiority of BAY 86-5047 over placebo (p = 0.67).
For participants who received BAY 86-5047, mean VAS scores decreased from 64.8 mm at baseline to 49.2 mm at week 12, a reduction of 15.6 mm (Figure 2 ). For women treated with placebo, mean VAS scores decreased by 19.4 mm over the same period, from 67.2 mm to 47.8 mm. These changes were not significantly different between the BAY 86-5047 and placebo groups (p = 0.45).
The proportion of participants taking analgesics decreased from 33.9% at baseline to 11.5% at week 12 in the BAY 86-5047 group, and from 44.4% to 15.4% over the same period in the placebo group (Figure 3) . There was no significant difference between the two treatment groups in terms of analgesic intake (p = 0.82). Moreover, for both groups of participants, there was little change in the intake of rescue medication from baseline. Overall, there was no clear relation between the change in VAS scores and the change in rescue medication intake (Figure 4) .
Secondary efficacy variables. Analysis of B&B scores showed similar trends in the two treatment groups (Figure 5) . There was no significant difference in total B&B scores for women treated with BAY 86-5047 or placebo (p = 1.0). There was also no significant difference between the groups for the individual components of B&B assessment, namely non-cyclic pelvic pain, dysmenorrhea and dyspareunia. Similarly, there was no significant difference between the treatment groups in terms of change in analgesic intake. At the end of the study, the proportion of patients treated with BAY 86-5047 whose condition was categorized by investigators as being "much improved" was 33.3%, compared with 28.5% of patients taking placebo. 
Safety
No safety concerns were identified from physical examination, vital signs, laboratory safety tests or electrocardiograms. AEs leading to dose reduction were principally of a gastrointestinal nature and occurred mainly in the BAY 86-5047 group (11 participants/20 AEs vs. one participant/one AE in the placebo group). Study medication was prematurely discontinued due to AEs in 11 participants (17 AEs) who received BAY 86-5047 and in four participants (four AEs) given placebo. Nausea and vomiting were the most common reasons for withdrawal (four and three patients, respectively, who received BAY 86-5047).
There were seven serious AEs, of which two were assessed by the investigators as possibly related to BAY 86-5047 treatment: one event of vertigo with no pathological findings on cerebral computed tomography scans, and one case of squamous epithelial cancer of the cervix in situ (cervical intraepithelial neoplasia III) with underlying human papilloma virus infection. The remaining five serious AEs, unrelated to treatment, consisted of three events of severe dysmenorrhea requiring hospitalization, one ankle fracture and one pregnancy that ended in miscarriage in the 6th gestational week. No safety concerns were identified from evaluation of these serious AEs.
Discussion
New therapies for endometriosis are needed, in particular novel drugs that target the pain and inflammatory pathways fundamental to the disease. Many potential drugs have shown promise in preclinical studies, but few have been tested in clinical trials (6) . Moreover, those that have reached this stage of development have so far yielded disappointing results. Many clinical studies of endometriosis treatments have been registered in clinical trial registries, but the results are often not published (19, 20) . These issues have shown limited progress in improving the treatment of women suffering from EAPP.
There is a growing body of evidence to support a role of inflammation in the pathophysiology of endometriosis. Indeed, it has been proposed recently that endometriosisassociated pain is largely attributable to activation of the innate immune system in response to tissue degeneration within endometriotic lesions (7) . Therefore, drugs that block inflammatory response pathways may enable direct targeting of a key source of endometriosis-associated pain. Blockade of the chemokine receptor, CCR1, in endometriosis is an attractive concept, based on its high expression levels both on peritoneal macrophages and within endometriotic lesions (8, 21) . Preclinical studies have demonstrated the ability of small-molecule antagonists to block the binding of ligands to CCR1 in vitro (22) . Such compounds have also been shown to inhibit CCL5/RANTES-mediated monocyte migration (23) and chemokine-induced upregulation of the integrin, CD11b, on macrophages (22, 24) . However, despite these promising findings, clinical investigations of CCR1 antagonists have, thus far, yielded disappointing results (11) .
The present study assessed the efficacy of the novel CCR1 antagonist, BAY 86-5047, when administered orally three times daily over 12 weeks in women with endometriosis. During the treatment of patients with multiple sclerosis, this dosing regimen was shown to result in plasma drug concentrations of BAY 86-5047 exceeding 100 mg/mL and receptor blockade of at least 90% (13) . A previous study suggested that this level of CCR1 receptor blockade may be necessary to observe efficacy in preclinical models (24) . Despite this, the present study failed to demonstrate the efficacy of BAY 86-5047 to treat EAPP. Although treatment with BAY 86-5047 resulted in a reduction in VAS score and analgesic intake, similar reductions were also seen in women who received placebo, and there was no significant difference between the two treatment groups. Several factors may underlie the lack of efficacy of BAY 86-5047 in this study. The failure of previous trials has been attributed to the selected drug doses being too low to achieve adequate CCR1 inhibition in vivo (24) . However, many of these clinical trials have presented evidence of the pharmacodynamic activity of their selected CCR1 antagonists. Administration of the CCR1 antagonist CP-481,715 to patients with rheumatoid arthritis resulted in decreased monocyte infiltration into synovial tissue (25) and the drug exhibited dose-dependent CCR1 inhibition in a phase 1 evaluation of the compound (22) . Despite these promising results, a subsequent phase 2 study showed no benefit of CP-481,715 on disease progression when compared with placebo (11) . Similarly, although administration of BAY 86-5047 to patients with multiple sclerosis decreased monocyte activation in vivo (13), there was no reduction in the cumulative number of newly active lesions in patients treated with the drug vs. placebo after 16 weeks.
These pharmacodynamic findings suggest that the lack of clinical efficacy of CCR1 antagonists cannot be attributed to suboptimal dosing, and other explanations must be considered. The disease pathophysiology of endometriosis may be too complex to be modulated by CCR1 antagonism alone. In addition, preclinical models are not always representative of disease in humans (26) . In the treatment of endometriosis, and in other inflammatory conditions, it may be that additional pathological mechanisms act to counterbalance CCR1 antagonism. This could involve the compensatory up-regulation of other chemokine receptors (11) , which maintains inflammatory signaling during disease pathogenesis. Thus, a multi-targeted approach may be warranted, for example, combining CCR1 antagonists with inhibitors of other chemokine receptors or drugs targeted at other components of the inflammatory immune response.
A further possibility is that aspects of the study population and clinical trial design may not have been appropriate for evaluating the efficacy of BAY 86-5047. Information on the stage of endometriosis was not known with certainty for all women so we cannot exclude the possibility that the two study groups might have been heterogeneous in this regard and that this masked any beneficial effects of the compound. Moreover, the methods used to detect EAPP might not have been sufficiently sensitive to detect differences between the treatments. In our opinion both of these possibilities are unlikely, given that there was no ambiguity in the effects on the efficacy outcomes seen with both placebo and BAY 86-5047 treatments.
It should also be considered that the disease stage at which drug intervention is initiated may have impacted on the response to treatment; clinical interventions may be effective only at particular points in the natural history of a given disease (27) . Our findings are based on a short-term study in a small number of patients; however, the trial was adequately powered to detect clinically relevant differences between the treatment groups.
One interesting finding from this study was the observation of a significant placebo effect, which has also been observed in other clinical trials of endometriosis therapies. The study was designed to detect a minimally important clinical difference between the treatment and placebo groups of 25 mm, based on literature showing mean reductions in 12-week VAS scores in the range of 0-20 mm for placebo groups (28) (29) (30) . This non-inferiority margin is notably higher than the 10-mm difference validated by Gerlinger et al. (18) on the basis of findings from two placebo-controlled studies in endometriosis. In the present study, the absolute reduction in VAS score observed for women receiving placebo was considerable (19.4 mm, or 29%), and was numerically higher than the reduction in the BAY 86-5047 group. This highlights the importance of conducting placebo-controlled studies in the evaluation of novel therapies for the treatment of endometriosis.
Conclusion
The results of this study indicate that BAY 86-5047 (600 mg three times daily) is ineffective for the treatment of women with EAPP. A greater incidence of AEs was observed among patients treated with BAY 86-5047 than those who received placebo, but overall the study drug was considered to be well tolerated. Subsequent to this study, the development of BAY 86-5047 was discontinued. The lack of efficacy of CCR1 antagonists in other indications may suggest that CCR1 antagonism is insufficient as a stand-alone therapy for the treatment of inflammatory diseases. New targets for treatment of the underlying pain and inflammatory pathways fundamental to endometriosis, and increasing knowledge of these pathological mechanisms, remain an important priority for future research.
